News Search Results
Jul 30, 2024, 10:00 ET VGXI, accepted as a Member of the US Government's Rapid Response Partnership Vehicle (RRPV)
GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) headquartered in Seoul, South Korea is an international biotechnology company and a leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. GeneOne has recently expanded
More news about: VGXI, Inc.
Jul 30, 2024, 09:11 ET Dr. Russel Kaufman, Renowned Medical Innovator and Business Leader, Joins Immorta Bio's Board of Directors
scientific reports and his work has garnered more than 2,000 citations. About Immorta Bio Immorta Bio is a longevity-focused biotechnology company developing efficient and practical personalized cellular therapeutic platforms focused on Treating Diseases of Aging and Treating Aging
More news about: Immorta Bio, Inc.
Jul 30, 2024, 09:00 ET MycoWorks unveils new material application of innovative Fine Mycelium™ technology
SAN FRANCISCO, July 30, 2024 /PRNewswire/ -- Biotechnology company
More news about: MycoWorks
Jul 30, 2024, 09:00 ET Inimmune publishes positive proof of mechanism for TLR4 Agonist INI-2004 in Allergic Rhinitis
Evans. About Inimmune Corporation Inimmune Corp. (Missoula, MT) is a privately held biotechnology company focused on the discovery and development of innovative immunotherapeutics, adjuvants, and vaccines. Inimmune is harnessing the human immune
More news about: Inimmune
Jul 30, 2024, 08:15 ET Pinetree Therapeutics Closes $17 Million in Series A Funding to Advance AbReptor™ Protein Degradation Platform and Portfolio Programs
July 30, 2024 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree" or the "Company"), an emerging biotechnology company pioneering next-generation targeted protein degraders (TPD) to combat drug resistance in oncology and beyond, today announced the successful
More news about: PineTree Therapeutics
Jul 30, 2024, 08:05 ET Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update
replay for 90 days after the call via the Rigel website. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Jul 30, 2024, 08:01 ET NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced the signing of an exclusive license agreement, providing MThera
More news about: NeuroBo Pharmaceuticals, Inc.
Jul 30, 2024, 07:00 ET Orna Therapeutics Appoints Nobel Laureate Carolyn Bertozzi, Ph.D., to Scientific Advisory Board
WATERTOWN, Mass., July 30, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines, including panCAR™ in vivo CAR therapies for oncology
More news about: Orna Therapeutics
Jul 30, 2024, 07:00 ET Genexys BioMed Awarded $320K SBIR Grant to Advance Novel Cystic Fibrosis Gene Therapy
CINCINNATI, July 30, 2024 /PRNewswire/ -- Genexys BioMed, a pre-clinical stage biotechnology company developing a novel non-viral, non-lipid genetic medicine platform for the treatment of cystic fibrosis (CF) and other genetic diseases,
More news about: Genexys BioMed
Jul 30, 2024, 07:00 ET Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
July 30, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Jul 30, 2024, 03:13 ET Alamar Biosciences Establishes European Headquarters and Distribution Center in Milan, Italy
reliably.Commitment to Growth: This expansion underscores Alamar Biosciences' commitment to growth and innovation in the biotechnology sector, as well as its dedication to improving global healthcare outcomes.Strategic Location: Milan,
More news about: Alamar Biosciences, Inc.
Jul 30, 2024, 03:13 ET Alamar Biosciences Establishes European Headquarters and Distribution Center in Milan, Italy
reliably.Commitment to Growth: This expansion underscores Alamar Biosciences' commitment to growth and innovation in the biotechnology sector, as well as its dedication to improving global healthcare outcomes.Strategic Location: Milan,
More news about: Alamar Biosciences, Inc.
Jul 30, 2024, 00:56 ET Analog Devices與Flagship Pioneering達成策略合作，將加速推動全數位化生物世界發展
Sana Biotechnology (NASDAQ:SANA)、Generate Biomedicines、
More news about: ADI
Jul 29, 2024, 10:30 ET Prefilled Syringes Market worth $13.1 billion by 2030 driven by Rising Chronic Illness Rates | MarketsandMarkets™
Gerresheimer AG excels in medicine packaging and drug delivery solutions, offering a comprehensive range of products for the pharmaceutical, healthcare, biotechnology, and well-being sectors. The company's operations are divided into three segments: Plastics & Devices, Primary Packaging Glass, and Advanced
More news about: MarketsandMarkets
Jul 29, 2024, 10:15 ET Veterinary Supplements Market to Reach US$ 15.2 Billion by 2031, Driven by Increased Focus on Pet Health & Wellness | Report by Transparency Market Research, Inc.
Red Biotechnology Market - The global red biotechnology market is projected to advance at a CAGR of 5.6% from 2022 to 2031.
More news about: Transparency Market Research
Jul 29, 2024, 10:15 ET Meal Replacement Products Market Poised for Growth of USD 23.1 Billion by 2034 | Future Market Insights, Inc.
to food ingredients, nutrition & health solutions, animal nutrition, and marine nutrients. She is also well-versed in the pharmaceuticals, biotechnology, retail, and chemical sectors, where she advises market participants to develop methodologies and strategies that deliver results. Her
More news about: Future Market Insights
Jul 29, 2024, 10:02 ET Dental Implant Abutment Systems Market size is set to grow by USD 560.5 million from 2024-2028, Increasing prevalence of dental diseases boost the market, Technavio
challenge. Key market players include Adamas Implants Ltd., Argen Corp., Arum Europe GmbH, Bio3 Implants GmbH, Bioconcept Co. Ltd., Bone System Srl, BTI Biotechnology Institute S.L., Cendres Metaux Management SA, Cortex Dental Implants Industries Ltd., Danaher Corp., Dentsply Sirona Inc., DESS Dental Smart Solutions,
More news about: Technavio
Jul 29, 2024, 10:01 ET Biotech API Manufacturing Services Market to Reach US$ 73 Billion by 2031, Driven by Surge in Global Geriatric Population | Report by Transparency Market Research, Inc.
Red Biotechnology Market - The global red biotechnology market is projected to advance at a CAGR of 5.6% from 2022 to 2031.
More news about: Transparency Market Research
Jul 29, 2024, 08:45 ET Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on its ovarian cancer CAR-T therapy clinical trial at
More news about: Anixa Biosciences, Inc.
Jul 29, 2024, 08:00 ET Akebia Therapeutics to Present at Upcoming Investor Conferences
purpose to better the lives of people impacted by kidney disease, today announced participation in two investor conferences in August: BTIG virtual Biotechnology Conference, August 5-6, 2024, and Canaccord Genuity (CG) 44th Annual Growth Conference, August
More news about: Akebia Therapeutics, Inc.
Jul 29, 2024, 08:00 ET Versatope Receives Grants to Support Malaria Vaccine Development
Mass., July 29, 2024 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics announced today it has received a Phase 2 Small Business Innovation Research (SBIR) grant from
More news about: Versatope Therapeutics, Incorporated
Jul 29, 2024, 08:00 ET Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Jul 29, 2024, 07:30 ET Stealth BioTherapeutics Completes Mid-Cycle Review Meeting on Elamipretide for the Treatment of Barth Syndrome
July 29, 2024 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced
More news about: Stealth BioTherapeutics Inc.
Jul 29, 2024, 07:30 ET Priovant Therapeutics Announces Completion of Enrollment in Global Phase 3 Study Evaluating Brepocitinib in Dermatomyositis (VALOR)
to providing further updates as we reach upcoming milestones in 2024 and 2025." About Priovant Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead
More news about: Priovant Therapeutics
Jul 29, 2024, 07:00 ET GSK and Flagship Pioneering partner to discover novel medicines and vaccines
Sana Biotechnology (NASDAQ: SANA),
More news about: Flagship Pioneering